New Sciences,
Better Experience
Organoid Science leads sustainable future industries and creates social value through innovative medical technologies and global leadership in organoids.
Organoid Based High-End Technology
Organoid Science leads sustainable future industries and creates social value through innovative medical technologies and global leadership in organoids.
ATORM
Organoid Based Regenerative Medicine
Provides fundamental treatment for various diseases that are difficult to treat with general medicine
Unlike existing regenerative treatments, provides treatment through direct regenerative mechanisms
ODISEI
Organoid Based Drug Evaluation
Addressing the astronomical cost of new drug development and the lack of non-clinical evaluation models for new modality drugs
Providing alternative animal testing methods in accordance with animal welfare and FDA/EMA animal testing minimization policies
PODOtx
Organoid Enabled Precision Oncology
Reflecting the characteristics of each patient and ensuring intuitive response
High sensitivity, specificity, and accuracy
Expansion
Products for Organoid Culture
Research products for organoid culture
Cell therapy production agency
3D cultured organ analogues
reproduce the structure and function of actual organs
1
2
3
Reproducing long-term specific functions
The era of Organoids is already here.
ORGANOIDSCIENCES utilizes organ-specific adult stem cells to develop next-generation regenerative therapies.
Our patient-derived organoids closely mimic human biology, enabling a cutting-edge drug development platform for breakthrough discoveries.
Advanced regenerative medicine law, commercialization of organoid regenerative therapy through national advanced strategic technology
After the completion of the clinical trial of the first-generation method, prescriptions from medical institutions are expected to start in 2027
Leap forward as a leading global commercialization company by promoting full-scale domestic sales and global commercialization (LO) in 2028
U.S. FDA Modernization Act, Regulation of Organoid Evaluation Methods by the Korean Ministry of Food and Drug Safety
ODISEI will be commercialized from 2021 and achieve continuous sales growth. It aims to achieve approximately KRW 30 billion in 2028 by continuing to grow after reaching KRW 4 billion in 2025.
The choice for industry’s leading partners
Take the Next Step
with ORGANOIDSCIENCES
Partner with ORGANOIDSCIENCES to drive groundbreaking organoid research and next-generation cell therapies. Be part of a biotech revolution shaping the future of healthcare.
